Progression of antiphospholipid antibody syndrome to catastrophic antiphospholipid antibody syndrome acutely with cessation of antithrombotic therapy

Internal Medicine Journal

Volumn 42, Issue 5, 2012, Pages 585-591

  Katikireddi, V S ^a   Kandiah, D A ^a,b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Antiphospholipid antibody; Antiphospholipid antibody syndrome; Antithrombotic therapy; Catastrophic antiphospholipid antibody syndrome; Warfarin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CEFALOTIN; GENTAMICIN; HEPARIN; IMMUNOGLOBULIN; METRONIDAZOLE; NORETHISTERONE; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; TRIMETHOPRIM; TROPONIN I; WARFARIN;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOGENIC SHOCK; CASE REPORT; CATASTROPHIC ANTIPHOSPHOLIPID ANTIBODY SYNDROME; DEEP VEIN THROMBOSIS; DISEASE COURSE; DISEASE SEVERITY; DYSPNEA; ESCHERICHIA COLI INFECTION; EXTRACORPOREAL OXYGENATION; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOMODULATION; INTENSIVE CARE; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MALE; MEDICAL HISTORY; MENORRHAGIA; MITRAL VALVE REGURGITATION; PARTIAL THROMBOPLASTIN TIME; PLASMAPHERESIS; PRIORITY JOURNAL; SUDDEN DEATH; THORAX PAIN; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT WITHDRAWAL; URINARY TRACT INFECTION;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; CATASTROPHIC ILLNESS; DISEASE PROGRESSION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; WITHHOLDING TREATMENT;

EID: 84861425435     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2012.02768.x     Document Type: Article

References (27)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R etal. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Lim W. Antiphospholipid antibody syndrome. Hematology Am Soc Hematol Educ Program 2009; 1: 233-9.
3. Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC etal. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530-4.
4. Fonseca AG, D'Cruz DP. Controversies in the antiphospholipid syndrome: can we ever stop warfarin? J Autoimmune Dis 2008; 5: 6-17.
5. Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gomez-Puerta JA, Ramos-Casals M etal. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006; 54: 2568-76.
6. Asherson RA. The catastrophic antiphospholipid (Asherson's) syndrome in 2004 - a review. Autoimmun Rev 2005; 4: 48-54.
7. Kandiah DA, Sali A, Sheng Y, Victoria EJ, Marquis DM, Coutts SM etal. Current insights into the 'antiphospholipid' syndrome: clinical, immunological, and molecular aspects. Adv Immunol 1998; 70: 507-63.
8. Fischetti F, Durigutto P, Pellis V, Debeus A, Macor P, Bulla R etal. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106: 2340-6.
9. Finazzi G. Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? No. Intern Emerg Med 2008; 3: 197-200.
10. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L etal. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007; 56: 2382-91.
11. Tuthill JI, Khamashta MA. Management of antiphospholipid syndrome. J Autoimmun 2009; 33: 92-8.
12. Erkan D, Lockshin MD. Antiphospholipid syndrome. Curr Opin Rheumatol 2006; 18: 242-8.
13. Brey RL, Stallworth CL, McGlasson DL, Wozniak MA, Wityk RJ, Stern BJ etal. Antiphospholipid antibodies and stroke in young women. Stroke 2002; 33: 2396-400.
14. Meroni PL, Peyvandi F, Foco L, Bernardinelli L, Fetiveau R, Mannucci PM etal. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost 2007; 5: 2421-8.
15. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002; 41: 924-9.
16. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998; 104: 332-8.
17. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR etal. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.
18. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 454S-545S.
19. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J etal. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.
20. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J etal. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-53.
21. Tunariu N, Gibbs SJ, Win Z, Gin-Sing W, Graham A, Gishen P etal. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007; 48: 680-4.
22. Cervera R. Catastrophic antiphospholipid syndrome (CAPS): update from the 'CAPS Registry'. Lupus 2010; 19: 412-18.
23. Asherson RA, Shoenfeld Y. The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome - molecular mimicry? J Rheumatol 2000; 27: 12-14.
24. Finazzi G. The Italian registry of antiphospholipid antibodies. Haematologica 1997; 82: 101-5.
25. Philipp CS. Antifibrinolytics in women with menorrhagia. Thromb Res 2011; 127(Suppl 3): S113-15.
26. Marret H, Fauconnier A, Chabbert-Buffet N, Cravello L, Golfier F, Gondry J etal. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol 2010; 152: 133-7.
27. Pierangeli SS, Erkan D. Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? Lupus 2010; 19: 475-85.